Findings

What do systematic reviews say?

78 questions · 79 findings · 7 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 19 · 24.1%GRADE not reported 9 · 11.4%Very low 14 · 17.7%Low 13 · 16.5%Moderate 20 · 25.3%High 4 · 5.1%

Oral azithromycin vs topical tetracycline

Adverse effects · people (any age) with active trachoma

1 finding from 1 review

Antibiotics for trachoma 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6002 participants
GRADE not reported

Oral azithromycin vs control

Active trachoma · people (any age) with active trachoma

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for trachoma 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral azithromycin vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 549 participants
High

Oral azithromycin vs placebo

Time to next pulmonary exacerbation · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 796 participants
Moderate

Oral azithromycin vs placebo

Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 748 participants
Moderate

Oral azithromycin vs placebo

Hospital admissions · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 445 participants
High

Oral azithromycin vs placebo

New acquisition of CF pathogens: PA · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 282 participants
Moderate

Oral azithromycin vs placebo

QoL · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 177 participants
Moderate

Summary of findings ‐ weekly azithromycin vs daily azithromycin

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 208 participants
Moderate

Summary of findings ‐ weekly azithromycin vs daily azithromycin

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 208 participants
Moderate

Summary of findings ‐ weekly azithromycin vs daily azithromycin

Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 208 participants
Moderate

Summary of findings ‐ weekly azithromycin vs daily azithromycin

Hospital admissions · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 208 participants
Moderate

Summary of findings ‐ weekly azithromycin vs daily azithromycin

New acquisition of CF pathogens: PA · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ weekly azithromycin vs daily azithromycin

QoL · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 208 participants
Moderate

Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin

Adverse events · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin

Hospital admissions · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin

New acquisition of CF pathogens: PA · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin

QoL · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulised azithromycin vs azithromycin

FEV1 % predicted: absolute change from baseline · children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Summary of findings ‐ nebulised azithromycin vs azithromycin

Time to next pulmonary exacerbation · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found